证券代码：000504 证券简称：南华生物 公告编号：2025-024 南华生物医药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动的情况介绍 南华生物医药股份有限公司（以下简称"公司"或"南华生物"）股票（证 券简称：南华生物，证券代码：000504）于2025年4月24日、2025年4月25日、2025 年4月28日连续三个交易日内收盘价格跌幅偏离值累计超过20%，根据《深圳证券 交易所交易规则》的有关规定，属于股票异常波动情形。 二、公司关注并核实情况 （一）公司核查情况 针对公司股票交易异常波动，公司对有关事项进行了核查，对影响公司股票 异常波动的情况说明如下： 1.公司于2025年4月22日对2024年年度业绩预告进行了修正，具体内容详见 《关于2024年年度业绩预告修正暨可能被实施退市风险警示的公告》（公告编号： 2025-011）。除此之外，公司前期披露的信息不存在需要更正、补充之处； 2.近期公共传媒未出现报道了可能或已经对本公司股票交易价格产生较大 影响的未公开重大信息； 3.近期公司 ...

Financial Performance - In 2024, the company's total profit, net profit, and net profit after deducting non-recurring gains and losses were all negative, with operating revenue falling below 300 million RMB, triggering delisting risk warnings[6]. - The company's operating revenue for 2024 was ¥134,447,796.85, a decrease of 1.71% compared to ¥136,790,924.97 in 2023[22]. - The net profit attributable to shareholders for 2024 was -¥19,846,018.35, an improvement of 29.56% from -¥28,172,625.54 in 2023[22]. - The net cash flow from operating activities decreased by 86.79% to ¥4,793,582.85 in 2024, down from ¥36,276,713.53 in 2023[22]. - The total assets at the end of 2024 were ¥608,169,817.97, a decline of 21.16% from ¥771,382,516.09 at the end of 2023[23]. - The net assets attributable to shareholders decreased by 7.72% to ¥237,095,180.02 at the end of 2024, compared to ¥256,941,198.37 at the end of 2023[23]. - The company reported a basic earnings per share of -¥0.06 for 2024, improving from -¥0.09 in 2023[22]. - The company reported a main business revenue of less than 300 million yuan, indicating insufficient scale to cover operating costs and ongoing losses[105]. Strategic Adjustments - The company plans not to distribute cash dividends, issue bonus shares, or convert reserves into share capital[7]. - The company has undergone a strategic adjustment in its major shareholder structure, with the largest shareholder holding 25.58% of the total shares after a transfer of shares[21]. - The company has established several subsidiaries, including Hunan Caixin Energy Conservation Technology Co., Ltd. and Nanhua Biyouhan (Hunan) Biotechnology Co., Ltd.[93]. - The company completed the acquisition of Hunan Caixin Energy Conservation and Environmental Protection Technology Co., Ltd. in July 2024, with full control over assets and management[171]. - The company has established a joint venture, Nanhua Biopharmaceutical (Hunan) Technology Co., Ltd., in September 2024, maintaining control over financial and operational teams[171]. Market and Industry Insights - The global stem cell manufacturing market is projected to grow from $15.08 billion in 2024 to $24.45 billion by 2029, indicating a strong growth potential in the industry[33]. - The Chinese stem cell market is expected to reach approximately ¥265 billion in 2024, with the collection, preparation, and storage segment nearing ¥160 billion[33]. - The company's energy-saving and environmental protection industry output value reached 9.8 trillion yuan in 2024, with expectations to grow to approximately 15 trillion yuan by 2030, indicating a rapid expansion of the market scale[34]. Research and Development - The company has established 10 innovation platforms, including provincial and national research centers, enhancing its competitive advantage in the biopharmaceutical industry[50]. - The company has over 90 patents and software copyrights, reflecting its commitment to research and development in both biopharmaceutical and energy-saving technologies[51]. - The company is developing a serum-free culture system for umbilical mesenchymal stem cells, which is expected to enhance safety and expand product offerings in pediatric disease treatment[68]. - The company is exploring exosome separation and purification processes, aiming to develop cell therapy products for neonatal acute respiratory distress syndrome[68]. - The company is enhancing its product pipeline with innovative cell therapy products, aiming to capture early opportunities in clinical research and applications[69]. Operational Efficiency - The company is implementing cost reduction and efficiency improvement measures to enhance revenue and profitability[105]. - The company has improved production efficiency and reduced costs through technological innovations in cell culture systems and automation[55]. - The company aims to reduce energy consumption for enterprises through comprehensive energy-saving project investments, focusing on urban lighting system retrofitting and energy efficiency in industrial and commercial buildings[37]. - The company has committed to improving production efficiency and operational effectiveness through resource optimization and internal management[96]. Governance and Compliance - The company maintains independent operations and governance, ensuring no interference from controlling shareholders in decision-making processes[116]. - The board of directors consists of 7 members, including 3 independent directors, adhering to governance regulations[117]. - The company ensures timely and accurate information disclosure, with designated platforms for investor communication[120]. - The company has established a complete legal governance structure and internal management system to ensure independent operation[187]. - The company is committed to maintaining transparency and compliance with stock exchange regulations[157]. Financial Management - The company has reduced interest-bearing liabilities, resulting in a significant decrease in financial expenses by 102.62%[67]. - The company reported a net cash flow from operating activities of CNY 4,793,582.85, a significant decrease of 86.79% compared to the previous year[73]. - The company has committed to minimizing related party transactions and ensuring fair pricing in unavoidable transactions[191]. - The company has maintained a continuous audit service with Tianjian Accounting Firm for 11 years, with an audit fee of 613,500 CNY[198]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion yuan[131]. - The company plans to invest 100 million yuan in new technology to improve production efficiency over the next two years[131]. - The company aims to enhance its core technology and focus on R&D in stem cells, immune cells, beauty products, and energy conservation by 2025[95]. - The company plans to enhance its beauty business by increasing investment and technological development to combine biotechnology with beauty products, aiming for revenue growth[97].

Financial Performance - The company's revenue for Q1 2025 was ¥22,453,576.28, a decrease of 13.55% compared to ¥25,973,854.69 in the same period last year[5] - The net loss attributable to shareholders was ¥2,218,632.26, an improvement of 19.92% from a loss of ¥2,770,653.53 in the previous year[5] - Net profit for the current period is -¥6,522,060.18, compared to -¥2,846,531.87 in the previous period, indicating a significant increase in losses[19] - Total operating revenue for the current period is ¥22,453,576.28, a decrease of 13.7% from ¥25,973,854.69 in the previous period[18] - Total operating costs increased to ¥30,056,727.81, up 0.3% from ¥29,981,563.79 in the previous period[18] - The total comprehensive income for the current period is -¥6,522,060.18, compared to -¥2,846,531.87 in the previous period[19] Cash Flow and Liquidity - The net cash flow from operating activities improved by 45.15%, reaching -¥825,292.27 compared to -¥1,504,744.35 in the prior year[5] - Operating cash flow for the current period is -¥825,292.27, an improvement from -¥1,504,744.35 in the previous period[21] - Cash and cash equivalents at the end of the period decreased to ¥141,375,896.11 from ¥212,597,686.65 in the previous period[22] - The company's cash and cash equivalents decreased by 31.81% to ¥141,405,896.11, primarily due to investments in bank wealth management products[8] - Investment activities generated a net cash outflow of -¥63,643,586.86, compared to -¥118,821,316.99 in the previous period, indicating reduced cash outflow[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥601,914,862.34, a decrease of 1.03% from ¥608,169,817.97 at the end of the previous year[5] - Current assets decreased to CNY 389,870,377.50 from CNY 401,904,309.43, primarily due to a reduction in cash and cash equivalents[15] - The company's inventory decreased by 35.74% to ¥21,886,655.45, mainly due to reduced stock levels at subsidiaries[8] - Accounts receivable decreased from CNY 139,581,939.21 to CNY 124,633,751.11, a reduction of approximately 10.7%[15] - Total liabilities remained relatively stable, with a slight increase from CNY 326,171,710.73 to CNY 326,671,985.01[16] - The company's total equity decreased from CNY 281,998,107.24 to CNY 275,242,877.33, indicating a decline of about 2.7%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,992[11] - The largest shareholder, Hunan Caixin Industrial Fund Management Co., Ltd., holds 29.74% of the shares, totaling 98,150,852 shares[11] Earnings Per Share - The company's basic and diluted earnings per share improved to -¥0.0067, a 20.24% increase from -¥0.0084 in the same period last year[5] - The basic and diluted earnings per share for the current period are both -¥0.0067, compared to -¥0.0084 in the previous period[19] Research and Development - The company reported a significant increase in research and development expenses to ¥2,816,476.66, up from ¥2,184,441.44 in the previous period[18] Audit Status - The company has not undergone an audit for the first quarter report[23]

New Stock Issuance - Tian Gong Co., Ltd. issued shares at a price of 3.94[1] - Ze Run New Energy issued shares at a price of 33.06[1] Rights Issues and Trading Alerts - ST Xin Chao has a tender offer period from April 8, 2025, to May 7, 2025[1] - The second tender offer period for ST Xin Chao is from April 23, 2025, to May 22, 2025[1] - The last trading day for Pu Li Tui is in 14 trading days[1] - The last trading day for Pu Li Zhuang Tui is also in 14 trading days[1] Abnormal Fluctuations - Multiple stocks are flagged for severe abnormal fluctuations, including Dongfang Tong and Ningbo United[1] - A total of 14 stocks are noted for significant price volatility, with specific links to their announcements provided[1] Additional Trading Information - Various stocks have upcoming announcements and trading alerts, including ST Hua Peng and Bei Ding Co., Ltd.[1] - The report includes links to detailed announcements for each stock mentioned, ensuring transparency and accessibility for investors[1]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a long-term focus on domestic innovative drugs in the oncology field and AI medical investment opportunities [3][4]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.16%, outperforming the Wind All A index (1.15%) and the CSI 300 index (0.38%) [3][8]. - The upcoming ASCO conference is highlighted as a significant event for domestic innovative drug companies, with over 70 oral presentations and more than 10 major studies expected [3][4]. - The Ministry of Industry and Information Technology and six other departments issued a plan for the digital transformation of the pharmaceutical industry, aiming for significant advancements by 2027 and full coverage by 2030 [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector increased by 1.16% from April 21 to April 25, outperforming the Wind All A index and the CSI 300 index [3][8]. - Notable performers included medical research outsourcing (6.34%) and raw materials (4.72%), while blood products (-3.26%) and vaccines (-6.38%) continued to decline [3][9]. - Individual stock performances showed significant gains for Yong'an Pharmaceutical (31.4%), Shuyou Shen (28.4%), and Erkang Pharmaceutical (27.7%), while *ST Jiyuan (-43.2%), Nanhua Biological (-35.3%), and Shuangcheng Pharmaceutical (-27.7%) faced substantial losses [3][11]. Industry News and Key Company Announcements - On April 25, Kangfang Bio announced FDA approval for its drug Anike for the treatment of recurrent or metastatic nasopharyngeal carcinoma [12]. - The same day, Kangfang Bio also reported the approval of its PD-1/VEGF bispecific antibody for first-line treatment of specific lung cancer types [13]. - The digital transformation plan for the pharmaceutical industry aims to enhance competitiveness and quality management through AI and data integration by 2030 [3][4].

New Stock Listings - The new stock "Zhongjie Automobile" (code: 301560) is listed at an issuance price of 16.50[1] Rights Issues and Offers - Cash option for "AVIC Capital" (code: 600705) is available from April 23 to April 25, 2025[1] - Tender offer for "ST Xinchao" (code: 600777) is open from April 23 to May 22, 2025[1] - "ST Puli" (code: 300630) will enter the delisting arrangement period starting April 28, 2025[1] Market Alerts - "Guoguang Chain" (code: 605188) has reported severe abnormal fluctuations[1] - "Dongfang Tong" (code: 300379) also reported severe abnormal fluctuations[1] Other Announcements - "Huili B" (code: 900939) has a recent announcement linked to its trading activities[1] - "Zhejiang Rongtai" (code: 603119) has a recent announcement linked to its trading activities[1] - "ST Jiuyou" (code: 600462) has a recent announcement linked to its trading activities[1]

根据《深圳证券交易所股票上市规则》第9.3.1条规定，上市公司出现"最近一个会计年度经审计的利润 总额、净利润、扣除非经常性损益后的净利润三者孰低为负值，且扣除后的营业收入低于3亿元"的情形 时，公司股票交易将被实施退市风险警示，股票简称前将冠以"*ST"字样。南华生物此次修正后的业绩 数据，恰好触及了这一退市风险警示的红线。公司股票将于公告后停牌一个交易日，自复牌之日起，深 圳证券交易所便会对公司股票交易实施退市风险警示。这对于南华生物而言，无疑是一场严峻的考验， 而对于广大投资者来说，更是增加了投资的不确定性和风险。 2025年4月22日，南华生物医药股份有限公司（南华生物，000504）对外披露了关于2024年年度业绩预 告修正暨可能被实施退市风险警示的公告。市场分析认为，这一公告不仅宣告了公司业绩的"悲催性"反 转，更预示着公司或将面临退市风险警示，同时也为股民们带来了潜在的索赔可能。 公司业绩被大幅"修正"，盈利变亏损 资料显示，南华生物于2025年1月22日首次发布的2024年年度业绩预告，彼时公司预计呈现盈利态势。 然而，仅仅三个月后，公司便对这份业绩预告进行了大幅修正。修正后的数据显示，公司预 ...

南华生物医药股份有限公司 关于公司股票交易可能被实施退市风险警示的第三次提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 证券代码：000504 证券简称：南华生物 公告编号：2025-013 公司已于 2025 年 4 月 22 日在《中国证券报》《证券时报》《上海证券报》 《证券日报》和巨潮资讯网（www.cninfo.com.cn）上披露《关于 2024 年年度业 绩预告修正暨可能被实施退市风险警示的公告》（公告编号：2025-011）；于 2025 年 4 月 23 日在《中国证券报》《证券时报》《上海证券报》《证券日报》 和巨潮资讯网（www.cninfo.com.cn）上披露《关于公司股票交易可能被实施退 市风险警示的第二次提示性公告》（公告编号：2025-012）。 三、其他说明及相关风险提示 南华生物医药股份有限公司（以下简称"公司"）于 2025 年 4 月 22 日对外披露了《关 于 2024 年年度业绩预告修正暨可能被实施退市风险警示的公告》，预计公司 2024 年度净利 润、扣除非经常性损益后的净利润均为负值且扣 ...

证券代码：000504 证券简称：南华生物 公告编号：2025-014 南华生物医药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、股票交易异常波动的情况介绍 南华生物医药股份有限公司（以下简称"公司"或"南华生物"）股票（证 券简称：南华生物，证券代码：000504）于2025年4月21日、2025年4月22日、2025 年4月23日连续三个交易日内收盘价格跌幅偏离值累计超过20%，根据《深圳证券 交易所交易规则》的有关规定，属于股票异常波动情形。 二、公司关注并核实情况 （一）公司核查情况 针对公司股票交易异常波动，公司对有关事项进行了核查，对影响公司股票 异常波动的情况说明如下： 1.公司于2025年4月22日对2024年年度业绩预告进行了修正，具体内容详见 《关于2024年年度业绩预告修正暨可能被实施退市风险警示的公告》（公告编号： 2025-011）。除此之外，公司前期披露的信息不存在需要更正、补充之处； 2.近期公共传媒未出现报道了可能或已经对本公司股票交易价格产生较大 影响的未公开重大信息； 3.近期公司 ...

Core Viewpoint - Nanhua Biological (000504.SZ) significantly revised its 2024 annual performance forecast from a profit of 12.5 million to 15.5 million yuan to a loss of 19 million to 21 million yuan, triggering delisting risk warning conditions [1] Group 1: Performance Revision - The company’s 2024 net profit and net profit after deducting non-recurring gains and losses are both negative, with operating revenue below 300 million yuan, leading to a "*ST" designation for its stock [1] - The revision was attributed to return risks primarily related to the sales of the company's beauty products, as prior profit announcements were made before a comprehensive audit [5] Group 2: Business Transformation - Nanhua Biological has been transitioning towards beauty and anti-aging sectors, which are key areas of its recent business strategy, while previously being involved in real estate, media, biomedicine, and energy-saving industries [5] - The company has faced delisting risk warnings multiple times in the past due to consecutive years of losses, specifically in 2010, 2013, 2016, and 2019 [5] Group 3: Management and Control - The frequent changes in the company's business focus are linked to changes in its controlling shareholders, although the company asserts that there are no internal management issues or control deficiencies [5]